RA
AXSM icon

Rise Advisors’s Axsome Therapeutics AXSM Stock Holding History

Rise Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-80
Closed -$9.72K – 228
2025
Q3 		$9.72K Hold
80
– – ﹤0.01% 1013
2025
Q2 		$8.35K Hold
80
– – ﹤0.01% 1072
2025
Q1 		$9.33K Buy
+80
New +$9.11K ﹤0.01% 1019

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rise Advisors's AXSM Position: Q4 2025 in Review

Rise Advisors sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 80 shares — an estimated $9.72K sold.

Rise Advisors first reported a position in AXSM in Q1 2025 and held it in 3 quarters. The position peaked at $9.72K in Q3 2025. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

  • Rise Advisors reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 80 Axsome Therapeutics shares in Q4 2025, an estimated $9.72K.
  • Rise Advisors first reported a position in Axsome Therapeutics in Q1 2025 and held it in 3 quarters.
  • Rise Advisors's Axsome Therapeutics position peaked at $9.72K in Q3 2025.
  • 398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.